Literature DB >> 34094543

Cerebral metastasis during remission after immunotherapy for metastatic urothelial carcinoma: A case report.

Shohei Iwata1, Fusako Niimi1, Tetsuya Danno1, Sachi Honda1, Takeshi Azuma1.   

Abstract

Central nervous system (CNS) metastasis of urothelial carcinoma (UC) is rare. Immune checkpoint inhibitors, which were developed for the treatment of patients with advanced cancer, have limited efficacy against CNS metastases due to the unique immune microenvironment of the brain. The brain is an immune-privileged organ and is protected by the blood-brain barrier. However, the management of CNS metastases of UC is crucial to improving the prognosis. The present report describes two cases of cerebral metastasis occurring in the context of systemic disease control using immunotherapy. To the best of our knowledge, the present report is the first to describe a CNS metastasis during remission induced by immunotherapy. Copyright: © Iwata et al.

Entities:  

Keywords:  blood-brain barrier; central nervous system metastasis; immune checkpoint inhibitor; urothelial carcinoma

Year:  2021        PMID: 34094543      PMCID: PMC8165701          DOI: 10.3892/mco.2021.2307

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  4 in total

Review 1.  Brain metastases from transitional cell carcinoma of urinary bladder.

Authors:  R S Anderson; A M el-Mahdi; D A Kuban; E M Higgins
Journal:  Urology       Date:  1992-01       Impact factor: 2.649

Review 2.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

3.  High incidence of brain metastases in patients treated with an M-VAC regimen for advanced bladder cancer.

Authors:  R Dhote; P Beuzeboc; N Thiounn; T Flam; M Zerbib; B Christoforov; B Debré
Journal:  Eur Urol       Date:  1998       Impact factor: 20.096

Review 4.  Immunotherapy in CNS cancers: the role of immune cell trafficking.

Authors:  Nivedita M Ratnam; Mark R Gilbert; Amber J Giles
Journal:  Neuro Oncol       Date:  2019-01-01       Impact factor: 12.300

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.